Posted by Michael Wonder on 16 Nov 2024
Outcome statement - October 2024 DUSC meeting
15 November 2024 - The outcome statement from the October 2024 DUSC meeting is now available.
The DUSC reviewed the utilisation of the following PBS listed medicines:
- Dasatinib monohydrate - chronic myeloid leukaemia
- Nilotinib hydrochloride monohydrate - chronic myeloid leukaemia
- Idelalisib - non-Hodgkin's lymphoma
- Molnupiravir - viral infection
